NGM Biopharmaceuticals (NGM) Stock Analysis

What NGM Biopharmaceuticals does

NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering and developing innovative therapies for liver and metabolic ailments, retinal conditions, and various forms of cancer. The company's advanced product candidates include Aldafermin, a modified version of the human hormone fibroblast growth factor 19, which is currently undergoing Phase IIb clinical evaluation for non-alcoholic steatohepatitis (NASH). Another key asset, MK-3655, is an agonistic antibody designed to activate fibroblast growth factor receptor 1c-beta-klotho, also in Phase IIb trials for treating both type 2 diabetes and NASH. NGM's pipeline further encompasses NGM120, an antagonist antibody targeting GFRAL, in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II development for geographic atrophy; and NGM707, a dual antagonist monoclonal antibody (targeting immunoglobulin-like transcript 2/4) in Phase I/II trials for patients with advanced solid tumors. Additionally, the company is developing NGM831 and NGM438, both intended for the treatment of advanced solid tumors. NGM has established significant partnerships, including research, product development, and licensing agreements with Merck Sharp & Dohme Corp. A separate collaboration with Merck & Co., Inc. is dedicated primarily to creating new treatments for pressing unmet patient needs in retinal and cardiovascular-metabolic (CVM) diseases, such as heart failure. Established in 2007, NGM Biopharmaceuticals, Inc. maintains its corporate headquarters in South San Francisco, California.

Key metrics

ETFs linked to NGM

Broad-market and Healthcare sector ETFs an investor holding NGM Biopharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how NGM fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for NGM Biopharmaceuticals?

NGM Biopharmaceuticals trades under the ticker NGM on NASDAQ.

Which exchange is NGM listed on?

NGM is listed on NASDAQ.

What sector does NGM Biopharmaceuticals operate in?

NGM Biopharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze NGM in a portfolio?

PortView shows NGM's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.